Asset profile
Lobeglitazone · Duvie
Small molecule
Evidence outlook · registrational
Type 2 Diabetes: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. No upcoming registrational readout date is posted to the registry. Check News for topline announcements.
Also in development:MASH / NASH
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
92 competitors in this universe: 2 direct rivals (same mechanism and indication), 1 same-class, 89 same-indication; 35 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Lobeglitazone (Duvie): this drug | Phase 3 | Small molecule | PPAR-gamma | ||
| Rosiglitazone (Avandia) | Approved | Small molecule | PPAR-gamma | ||
| JT-001 | Phase 3 | Small molecule | PPAR-gamma | ||
| HSG4112 | Phase 2 | Small molecule | PPAR-gamma | ||
| Afrezza | Approved | Peptide | Insulin receptor (basal), Insulin | ||
| Alogliptin (Nesina) | Approved | Small molecule | DPP-4 | ||
| Bexagliflozin (Brenzavvy) | Approved | Small molecule | SGLT2 | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Ertugliflozin (Steglatro) | Approved | Small molecule | SGLT2 | ||
| Glipizide (Glucotrol) | Approved | Small molecule | Sulfonylurea receptor (SUR1) | ||
| Glyburide (Diabeta / Micronase) | Approved | Small molecule | Sulfonylurea receptor (SUR1) | ||
| Insulin Aspart (NovoLog / Fiasp) | Approved | Peptide | Insulin receptor | ||
| Insulin Degludec (Tresiba) | Approved | Peptide | Insulin receptor (basal) |
…and 77 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2029 (1)
September 2029 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.